United States

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

14 Dec 2017
Change (% chg)

$-0.78 (-7.81%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50
Thursday, 14 Dec 2017 07:30am EST 


Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍​
Friday, 20 Oct 2017 05:18pm EDT 

Oct 20 (Reuters) - Kalvista Pharmaceuticals Inc :Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing‍​.  Full Article

Kalvista Pharmaceuticals announces collaboration with Merck
Tuesday, 10 Oct 2017 07:30am EDT 

Oct 10 (Reuters) - Kalvista Pharmaceuticals Inc :Kalvista Pharmaceuticals announces collaboration with Merck.Kalvista Pharmaceuticals - ‍investigational intravitreal DME candidate KVD001 phase 2 clinical trial still planned to initiate in 2017​.Kalvista Pharmaceuticals Inc - ‍Merck acquires 9.9% stake in Kalvista in private placement​.Kalvista Pharmaceuticals Inc - deal includes ‍$37 million upfront fee plus potential milestone payments and sales royalties​.Kalvista Pharmaceuticals Inc - ‍Kalvista also has granted to Merck a similar option to acquire investigational orally delivered molecules for DME​.Kalvista - ‍under deal terms, co granted to Merck rights including an option to acquire KVD001 through a period following completion of phase 2 trial.Kalvista - Co will fund, retain control over planned phase 2 clinical trial of KVD001, development of investigational oral DME compounds through phase 2​.Kalvista - eligible to get payments associated with exercise of options by Merck, achievement of milestones for each program potentially total $715 million​.  Full Article

KalVista Pharmaceuticals reports Q1 loss per share of $0.51
Thursday, 14 Sep 2017 07:30am EDT 

Sept 14 (Reuters) - Kalvista Pharmaceuticals Inc :KalVista pharmaceuticals reports fiscal first quarter results.Q1 loss per share $0.51.Q1 revenue $100,000 versus $1.0 million.KalVista Pharmaceuticals Inc - ‍Intravitreal Diabetic Macular Edema Candidate KVD001 remains on track for Phase 2 in 2017​.KalVista Pharmaceuticals Inc - ‍cash and cash equivalents were $26.5 million as of July 31, 2017​.  Full Article

Kalvista Pharmaceuticals reports Q4 loss per share $0.43
Thursday, 27 Jul 2017 04:01pm EDT 

July 27 (Reuters) - Kalvista Pharmaceuticals Inc :Kalvista Pharmaceuticals provides operational update and reports fiscal fourth quarter and full year financial results.Q4 loss per share $0.43.  Full Article

Kalvista Pharmaceuticals enters into an at-market sales agreement with BTIG
Thursday, 13 Jul 2017 04:30pm EDT 

July 13 (Reuters) - Kalvista Pharmaceuticals Inc :Kalvista Pharmaceuticals Inc - on July 13, 2017 co entered into an at--market sales agreement with BTIG, LLC.Kalvista Pharmaceuticals - Kalvista may offer, sell, from time to time through BTIG, shares of its common stock, par value $0.001 per share - SEC filing.  Full Article

Kalvista Pharmaceuticals files for mixed shelf of upto $100 mln
Wednesday, 29 Mar 2017 05:04pm EDT 

Kalvista Pharmaceuticals Inc :Files for mixed shelf of upto $100 million - sec filing.  Full Article

Kalvista Pharmaceuticals reports Q3 loss per share $1.03
Thursday, 16 Mar 2017 04:15pm EDT 

Kalvista Pharmaceuticals Inc : Kalvista Pharmaceuticals reports fiscal third quarter results . Q3 loss per share $1.03 .Q3 revenue $200,000 versus $300,000.  Full Article

Sv Life Sciences Fund IV reports 26.6 pct passive stake in Kalvista Pharma - sec filing
Tuesday, 7 Feb 2017 06:14am EST 

Kalvista Pharmaceuticals Inc :SV Life Sciences Fund IV, l.p. reports 26.6 percent passive stake in Kalvista Pharmaceuticals Inc as of November 21, 2016 -sec filing.  Full Article

Kalvista pharmaceuticals files for resale of up to 7.83 mln shares by selling stockholders
Tuesday, 20 Dec 2016 06:20am EST 

Kalvista Pharmaceuticals Inc - :Files for resale of up to 7.83 million shares of co's common stock by selling stockholders - SEC filing.  Full Article